Cyber Monday Deal: Up to 60% off InvestingProCLAIM SALE

Novartis confirms 2015 guidance after first-quarter profit beat

Published 23/04/2015, 06:39
© Reuters. Swiss drugmaker Novartis' logo is seen at the company's plant in the northern Swiss town of Stein
NOVN
-

ZURICH (Reuters) - Swiss drugmaker Novartis (VX:NOVN) on Thursday maintained its 2015 guidance as it posted first-quarter core net income that beat expectations.

The group reported a 7 percent year-on-year fall in first-quarter net sales in continuing operations to $11.9 billion (7.91 billion pounds), while sales rose 3 percent at constant currencies. Total group net sales were $12.5 billion.

Novartis generated net income in continuing operations of $3.2 billion, down 4 percent in dollar terms on the same period last year but up 8 percent at constant currencies. Total group net income was $3.1 billion.

Analysts in a Reuters poll had forecast total group net sales of $12.6 billion and group core net income of $2.9 billion.

© Reuters. Swiss drugmaker Novartis' logo is seen at the company's plant in the northern Swiss town of Stein

"We are on track to deliver our full-year guidance," Chief Executive Joseph Jimenez said in a statement.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.